Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): preliminary results of a randomised, controlled, open-label, platform trial
Background Tocilizumab is a monoclonal antibody that binds to the receptor for interleukin
(IL)-6, reducing inflammation, and is commonly used to treat rheumatoid arthritis. We …
(IL)-6, reducing inflammation, and is commonly used to treat rheumatoid arthritis. We …
[HTML][HTML] Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
O Abani, A Abbas, F Abbas, M Abbas, S Abbasi… - The Lancet, 2021 - thelancet.com
Background In this study, we aimed to evaluate the effects of tocilizumab in adult patients
admitted to hospital with COVID-19 with both hypoxia and systemic inflammation. Methods …
admitted to hospital with COVID-19 with both hypoxia and systemic inflammation. Methods …
Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
J Chalmers, H Abo-Leyah, H Loftus, M Spears… - …, 2021 - discovery.dundee.ac.uk
Background In this study, we aimed to evaluate the effects of tocilizumab in adult patients
admitted to hospital with COVID-19 with both hypoxia and systemic inflammation. Methods …
admitted to hospital with COVID-19 with both hypoxia and systemic inflammation. Methods …
[HTML][HTML] Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
RECOVERY Collaborative Group - Lancet (London, England), 2021 - ncbi.nlm.nih.gov
Background In this study, we aimed to evaluate the effects of tocilizumab in adult patients
admitted to hospital with COVID-19 with both hypoxia and systemic inflammation. Methods …
admitted to hospital with COVID-19 with both hypoxia and systemic inflammation. Methods …
Tocilizumab administration for the treatment of hospitalized patients with COVID‐19: a systematic review and meta‐analysis
C Kyriakopoulos, G Ntritsos, A Gogali, H Milionis… - …, 2021 - Wiley Online Library
Tocilizumab has been repurposed against the 'cytokine storm'in the setting of coronavirus
disease 2019 (COVID‐19). Our aim was to evaluate the efficacy of tocilizumab in the …
disease 2019 (COVID‐19). Our aim was to evaluate the efficacy of tocilizumab in the …
[HTML][HTML] Tocilizumab in COVID-19: a meta-analysis, trial sequential analysis, and meta-regression of randomized-controlled trials
Abstract Purpose Interleukin-6 (IL-6) levels discriminate between patients with mild and
severe COVID-19, making IL-6 inhibition an attractive therapeutic strategy. We conducted a …
severe COVID-19, making IL-6 inhibition an attractive therapeutic strategy. We conducted a …
Tocilizumab in hospitalized patients with COVID-19 pneumonia
IO Rosas, N Bräu, M Waters, R Go, BD Hunter… - MedRxiv, 2020 - medrxiv.org
ABSTRACT BACKGROUND COVID-19 is associated with immune dysregulation and
hyperinflammation. Tocilizumab is an anti–interleukin-6 receptor antibody. METHODS …
hyperinflammation. Tocilizumab is an anti–interleukin-6 receptor antibody. METHODS …
[HTML][HTML] Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis, first update
IM Tleyjeh, Z Kashour, M Riaz, L Hassett… - Clinical Microbiology …, 2021 - Elsevier
Objectives Cytokine release syndrome with elevated interleukin-6 (IL-6) levels is associated
with multiorgan damage and death in severe coronavirus disease 2019 (COVID-19). Our …
with multiorgan damage and death in severe coronavirus disease 2019 (COVID-19). Our …
[HTML][HTML] Tocilizumab in hospitalized patients with COVID-19: a meta analysis of randomized controlled trials
Background To date, only dexamethasone has been shown to reduce mortality in
coronavirus disease-19 (COVID-19) patients. Tocilizumab has been recently added to the …
coronavirus disease-19 (COVID-19) patients. Tocilizumab has been recently added to the …
[HTML][HTML] Tocilizumab in patients hospitalized with Covid-19 pneumonia
C Salama, J Han, L Yau, WG Reiss… - … England Journal of …, 2021 - Mass Medical Soc
Abstract Background Coronavirus disease 2019 (Covid-19) pneumonia is often associated
with hyperinflammation. Despite the disproportionate incidence of Covid-19 among …
with hyperinflammation. Despite the disproportionate incidence of Covid-19 among …